Gara Jalqabaatti › Dhibee Qara › Oklahoma › Oklahoma City
Qorannoo klinikaalii Dhibee Qara Oklahoma City, OK keessatti
Qorannoo 19 Dhibee Qara f Oklahoma City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Vanguard Study: Testing a New Way to Screen for Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- University of Oklahoma Health Sciences Center, Oklahoma City
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Namoota walitti qabaa jiraSadarkaa 3
- Mercy Hospital Oklahoma City, Oklahoma City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Namoota walitti qabaa jiraSadarkaa 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Oklahoma, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Mercy Hospital Oklahoma City, Oklahoma City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Namoota walitti qabaa jiraSadarkaa 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Namoota walitti qabaa jiraSadarkaa 3
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2/3
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Oklahoma, Oklahoma City
Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Site 101, Oklahoma City
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Namoota walitti qabaa jiraSadarkaa 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Namoota walitti qabaa jiraSadarkaa 1
- Xencor Investigative Site, Oklahoma City
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Namoota walitti qabaa jiraQorannoo ilaalaa
- Hightower Clinical, Oklahoma City
Qorannoo Dhibee Qara magaalota biroo keessatti
- Houston, TXQorannoo 78
- Boston, MAQorannoo 62
- New York City, NYQorannoo 60
- Los Angeles, CAQorannoo 45
- Arlington, VAQorannoo 41
- Washington, DCQorannoo 41
- Chicago, ILQorannoo 41
- Baltimore, MDQorannoo 40
- Nashville, TNQorannoo 40
- St. Louis, MOQorannoo 39
- Columbus, OHQorannoo 37
- Philadelphia, PAQorannoo 36
Qorannoo biroo Oklahoma City keessatti
- Kansara Qara'a Non-Small CellQorannoo 28
- Kansarii OvariiQorannoo 28
- Kansa EndometiriyaaliiQorannoo 25
- Kansarii ColorectalQorannoo 22
- Kansarii ProstateQorannoo 21
- Saree OljooQorannoo 17
- Kansara MetastatikiiQorannoo 16
- Saree (Gosoota Hunda)Qorannoo 14
- Leukemia Myeloidii HamaaQorannoo 14
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 13
- Dukkana BladderQorannoo 11
- Kansarii PancreasQorannoo 11
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.